SIREN : 907821060
FD PHARMA is a French company founded 4 years ago, specialized in the sector Activités des sociétés holding. Based in LINGOLSHEIM (67380), this company of category PME shows in 2024 a net income positive of 77 k€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | N/C | N/C | N/C |
| Net income | 77 497 € | 47 817 € | -12 € |
| EBITDA | -5 722 € | -24 514 € | -12 € |
| Net margin | N/C | N/C | N/C |
In 2024, FD PHARMA generates positive net income of 77 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax.
-5 722 €
-5 722 €
77 497 €
The debt ratio (= Financial debt / Equity x 100) stands at 727%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 12%. Low autonomy: the company heavily depends on external financing (banks, suppliers). Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 11.8 years of cash flow to repay all financial debt. Beyond 7 years, banks generally consider credit risk as high.
726.634%
12.044%
11.842
In 2024, the debt ratio of FD PHARMA (726.63) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of FD PHARMA (12.0%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of FD PHARMA (11.84) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 7349.06. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
7349.06
-118.141
In 2024, the liquidity ratio of FD PHARMA (7349.06) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
In 2024, the interest coverage of FD PHARMA (-118.1x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 0 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 240 days. Excellent situation: suppliers finance 240 days of the operating cycle (retail model).
0 €
0 j
240 j
0 j
Based on 54 transactions of similar company sales
in 2024,
the value of FD PHARMA is estimated at
113 142 €
(range 72 160€ - 578 783€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Only this financial indicator is available for this company.
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare FD PHARMA with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of FD PHARMA is not publicly disclosed (confidential accounts filed with INPI).
Yes, FD PHARMA generated a net profit of 77 k€ in 2024.
The headquarters of FD PHARMA is located in LINGOLSHEIM (67380), in the department Bas-Rhin.
The tax return of FD PHARMA is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
FD PHARMA operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.